Tetraphase Submits NDA for Investigational Drug for Complicated Intra-Abdominal Infections
January 3rd 2018Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).
Read More